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Abstract Transglutaminase type II (TG2) is a pleiotropic
enzyme that exhibits various activities unrelated to its origi-
nally identified functions. Apart from post-translational mod-
ifications of proteins (peculiar to the transglutaminase family
enzymes), TG2 is involved in diverse biological functions,
including cell death, signaling, cytoskeleton rearrangements,
displaying enzymatic activities, G-protein and non-enzymatic
biological functions. It is involved in a variety of human
diseases such as celiac disease, diabetes, neurodegenerative
diseases, inflammatory disorders and cancer. Regulatory
mechanisms might exist through which cells control multi-
functional protein expression as a function of their sub-
cellular localization. The definition of the tissue and cellular
distribution of such proteins is important for the determina-
tion of their function(s). We investigate the sub-cellular lo-
calization of TG2 by confocal and immunoelectron micros-
copy techniques in order to gain an understanding of its
properties. The culture conditions of human sarcoma cells
(2fTGH cells), human embryonic kidney cells (HEK293TG)
and human neuroblastoma cells (SK-n-BE(2)) are modulated
to induce various stimuli. Human tissue samples of myocar-
dium and gut mucosa (diseased and healthy) are also ana-
lyzed. Immuno-gold labeling indicates that TG2 is localized
in the nucleus, mitochondria and endoplasmic reticulum un-
der physiological conditions but that this is not a stable
association, since different locations or different amounts of
TG2 can be observed depending on stress stimuli or the state
of activity of the cell. We describe a possible unrecognized
location of TG2. Our findings thus provide useful insights
regarding the functions and regulation of this pleiotropic
enzyme.
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Introduction
Transglutaminase type II (TG2) is expressed ubiquitously and
abundantly and has been implicated in a variety of cellular
processes, such as differentiation, cell death, inflammation,
cell migration and wound healing (reviewed in Fesus and
Piacentini 2002; Lorand and Graham 2003; Fésüs and
Szondy 2005; Collighan and Griffin 2009). It seems to exert
contradictory activities, including both pro- and anti-apoptotic
functions (Fésüs and Szondy 2005) and has been shown to be
involved in the maturation of autophagolysosomes (D'Eletto
et al. 2009) indicating that TG2 plays a role between apoptosis
induction and autophagy (Fimia and Piacentini 2010).
Aberrant activation of TG2 or deregulation of its func-
tion(s) is involved in a variety of human diseases, such as
celiac disease, diabetes, neurodegenerative diseases, multiple
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sclerosis and rheumatoid arthritis (Facchiano et al. 2006). A
role in inflammatory disorders and septic shock has also been
shown (Falasca et al. 2005, 2008). Moreover, multiple studies
have revealed elevated TG2 expression in many types of
cancer cells (Mehta et al. 2010).
To explain this plethora of observations, several points
have been considered such as the cell type investigated
(TG2 is particularly abundant in endothelial cells, fibroblasts
and monocytes/macrophages), the different experimental con-
ditions and stimuli utilized (Ca++, nucleotides, nitric oxide,
reactive oxygen species) and the distinct protein-protein inter-
actions in the local microenvironment, all of which might
regulate the activities of TG2 (Jeong et al. 2009). The sub-
cellular localization of TG2 has been suggested as another
important determinant of its functions. TG2 is believed to
create distinct molecular interactions in the different sub-
cellular compartments, which in turn exert diverse effects on
cellular physiology. Depending on its localization, TG2 pre-
sents var ious biochemical ac t iv i t ies , such as a
transglutaminase (TGase), G protein (Gh), kinase, protein
disulfide isomerase (PDI) and/or as an adaptor protein (Park
et al. 2010). At low calcium concentrations, under normal
physiological conditions, intracellular TG2 displays no
TGase activity, although it displays other activities including
those of Gh, kinase and PDI. TG2 is predominantly a cyto-
plasmic protein, although it is also found in the nucleus and
mitochondria, on the plasma membrane, in the extracellular
cell surface and in the extracellular matrix (ECM).
Extracellular TG2 is involved in wound healing and scarring,
tissue fibrosis and metastatic cancer (Aeschlimann and
Thomazy 2000). At the cell surface, TG2 has also been
implicated in cell adhesion as an adaptor protein and in
ECM remodeling via TGase activity (Bergamini et al. 2011).
TG2 has been shown to translocate dynamically depending on
the state of cell proliferation or in response to the elevation of
intracellular calcium concentrations (Korner et al. 1989;
Ientile et al. 2007).
Knowledge of the sub-cellular localization of TG2 has
greatly expanded recently but studies in the field primarily
rely on the biochemical analysis of fractionated samples.
However, for a faithful demonstration of enzyme sub-
cellular location, electron microscopy is the most accurate
technique in that it allows the visualization of morphological
events at high resolution. In this study, TG2 was studied by
the immuno-gold technique in order to investigate, at
the electron microscopy level, the presence of the pro-
tein in diverse sub-cellular compartments. TG2 ultra-
structural localization was analyzed in the context of a
variety of cell types and tissues and under diverse
conditions (physiological or non-physiological). The da-
ta obtained provide useful clues and insights with regard
to the way in which TG2 expression is modulated in
response to various stimuli.
Materials and methods
Cells and tissue samples
Various cell lines have been used to determine the intracellular
localization of TG2 and the way that enzyme expression is
modulated in response to diverse conditions.
The cell line 2fTGH (purchased from Cancer Research
Technology, London, UK) was derived from HT1080 human
sarcoma cells (Rani et al. 1996) and has been previously
established to express high TG2 levels (D'Eletto et al. 2012).
HEK293TG (human embryonic kidney) cells were stably
transfected with active wild-type TG2 as described previously
(Rossin et al. 2012). In brief, HEK293 cells (purchased from
American Type Culture Collection, Rockville, Mass., USA)
were transfected with the full-length human TG2 gene
inserted into the pLPCX vector by using Lipofectamine
2000 (Invitrogen, Life Technologies, Grand Island, N.Y.,
USA) according to the manufacturer's instructions and were
then selected for puromycin (Sigma-Aldrich, St. Louis, Mo.,
USA) resistance by using the antibiotic added to the culture
medium (2 μg/ml).
SK-n-BE(2) neuroblastoma cells (purchased from
American Type Culture Collection) were used to provide
further insight into current thinking regarding the involvement
of TG2 in the development of drug resistance in cancer cells.
Cells were cultured in Dulbecco's modified Eagle's medi-
um (Invitrogen, Life Technologies) supplemented with 10 %
fetal bovine serum, 2 mML-glutamine, 100 mg/ml streptomy-
cin and 100 units/ml penicillin (Sigma-Aldrich) in a 5 % CO2
incubator.
Human tissue samples, including intestinal and heart biop-
sies, were used as “in vivo” models.
Confocal microscopy
The 2fTGH cells were fixed in ice-cold ethanol/acetone (1:1)
at −20 °C for 10 min. Samples were briefly rinsed in
phosphate-buffered saline (PBS), permeabilized with 0.1 %
Triton X-100 in PBS for 5 min and blocked with 1 % bovine
serum albumin (BSA) and 10% normal goat serum in PBS for
30 min. Primary antibodies, namely mouse anti-TG2 (CUB
7402, Thermo Scientific, Rockford, Ill., USA), rabbit anti-
calreticulin antibody (Stressgen, Enzo Life Sciences,
Farmingdale, N.Y., USA), rabbit anti-p62/SQSTM1 (MBL,
Woburn, Mass., USA) and rabbit anti-Tom20 antibody (Santa
Cruz Biotechnology, Dallas, Texas, USA), were incubated for
1 h with the cells at room temperature. After being washed, the
cells were incubated with Alexa488- or Alexa594-
fluorochrome-coupled secondary antibodies directed against
rabbit or mouse (Molecular Probes, Life Technologies, Grand
Island, N.Y., USA).
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Coverslips were mounted in SlowFade-Anti-Fade
(Invitrogen, Life Technologies). Fluorescence was analyzed
with a TCS SP2 confocal laser scanning microscope (Leica
Microsystems, Wetzlar, Germany). Digital images obtained
separately in both channels through a 63× objective (zoom
factor 2×) were acquired with Leica Confocal Software.
Processing for electron microscopy
Cells or tissue samples were fixed with 4 % formaldehyde
(prepared fresh from paraformaldehyde) in 0.1 M sodium
cacodylate buffer (pH 7.4) containing 2.5 % sucrose for 2 h
at 4 °C. After being washed in sodium cacodylate buffer and
following dehydration in a series of increasing concentrations
of ethanol (70 % ethanol for 20 min; 95 % ethanol, two
changes for 20 min), samples were infiltrated with a mixture
of LR-White resin (Agar Scientific, Stansted, Essex, UK) and
95 % ethanol (1:l) for 2 h and with pure LR-White overnight
at 4 °C. Samples embedded into gelatin capsules filled with
LR-White were then transferred into an oven at 55 °C for 24 h
to polymerize.
Immunoelectron microscopy
For immunolabeling, ultrathin sections (60 nm thickness)
were washed three times with PBS and three times with PBS
containing 1 % BSA and 0.15 % glycine, followed by a 30-
min blocking step with 5 % normal goat serum. Samples were
incubated with the anti-TG2 (CUB 7402) diluted 1:25 for 1 h
at room temperature. Where indicated, an anti-calreticulin
antibody (Stressgen) was used. After being washed in PBS,
samples were incubated with appropriate secondary antibody
conjugated to 15-nm or 5-nm gold particles (BioCell, Cardiff,
UK). Sections were stained with 2 % uranyl acetate and
observed under a Zeiss EM900 transmission electron micro-
scope. Images were captured digitally with a Mega View II
digital camera (SIS, Soft Imaging System, Münster,
Germany).
Controls for immunostaining
The specificity of the immunoreaction was assessed in all
cases by omitting the primary antibodies from the labeling
protocol and incubating the sections only in the protein-gold-
conjugated secondary antibodies
Quantitative evaluation of labeling density
Quantitation of TG2 within enterocytes was assessed by
counting the numbers of gold particles per area of sectioned
microvilli. Fifty random digital electron microscope images of
the apical part of enterocytes (at a magnification of 20,000×)
were taken for each group of patients examined (3 celiac
patients and 3 patients with celiac disease in remission). The
area of microvilli and the number of gold particles were
measured on the images by using image-processing software
(analySIS 3.1; SIS), making it possible to draw a region of
interest (ROI) containing the brush border or a part of the
cytoplasm of individual cells. The density of gold labeling
was calculated and the differences between samples were
statistically evaluated by the Student's t-test.
Results
TG2 location inside the cell under normal conditions
Immunofluorescence microscopy of TG2 distribution re-
vealed a diffuse punctate labeling pattern inside the cells
(Fig. 1a, d). Double-immunofluorescence of TG2 with anti-
bodies directed against proteins specific for mitochondria
(Fig. 1b) and endoplasmic reticulum (ER; Fig. 1e) showed
that TG2 was sporadically associated with these organelles
(Fig. 1c, f). To characterize the nature of this widespread
localization inside the cell further, we performed a detailed
study of the presence of TG2 in various cell compartments by
immunoelectron microscopy.
Results obtained in HEK293TG cells, under normal culture
conditions, showed that the enzyme was localized at several
sites inside the cell. However, it never appeared interspersed
in the cytoplasm but was always associated with a cell struc-
ture, such as the nucleus, mitochondria, or plasma membrane.
The presence of TG2 in the nucleus has been reported by
others in various cell types, although no one has previously
demonstrated with which nuclear structure (nuclear mem-
brane, nucleoplasm, nucleolus, chromatin) it is associated.
Gold particles unequivocally revealed the presence of the
enzyme as being mostly associated with euchromatin
(Fig. 2a), confirming the notion that nuclear TG2 especially
impacts on the regulation of gene expression via post-
translational modification of and/or interaction with transcrip-
tional factors and related proteins. No particles are present at
the level of nucleolus (Fig. 2b); this indicates that, although
polyamine conjugates have been reported to be localized
within the nucleolus, the enzyme is normally not associated
with this organelle. Interestingly, during mitosis when tran-
scription is inhibited, TG2 was still associated with chromatin
but, in this case, it appeared specifically localized on con-
densed regions of chromosome (Fig. 2c). Although not a
typical mitochondrial protein, approximately half of the cell
content of TG2 has been reported to be associated with mito-
chondria (Rodolfo et al. 2004). Nevertheless, the immuno-
gold localization showed that, under normal basal conditions,
TG2 was rarely found on mitochondria (Fig. 3a, b); the
enzyme seemed to be associated with both the outer
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mitochondrial membrane and with the matrix (Fig. 3b). A cell
compartment that was not previously considered to be a site of
localization for TG2 was the ER. Our observations showed
positive immunoreaction associated with the ER (Fig. 3c, d).
In order to establish the nature of the membranous structures
under consideration, we performed double-immunoreactions
for calreticulin, a classic chaperone-like ER resident and
found that TG2 staining strongly overlapped with calreticulin
immunoreactivity (Fig. 3c, d).
Concerning the cell surface, our immuno-gold analysis of
TG2 demonstrated a low density of gold particles on the
plasma membrane of the cells under normal conditions
(Fig. 4). In addition, the label indicated that, when present,
the enzyme was preferentially located on cell surface projec-
tions (Fig. 4).
A large number of TG2 substrates are proteins involved in
the organization of the cytoskeleton. Upon activation by Ca2+,
TG2 contributes to the organization of the cytoskeleton by
cross-linking various cytoskeletal proteins, i.e., microtubule
protein tau, b-tubulin, actin, myosin, spectrin, thymosin b,
troponin T and vimentin (Esposito and Caputo 2005; Kim
et al. 2008). TG2 might also regulate contractile performance
by means of its function as an adrenergic-receptor-coupled G
protein and its important role in stabilizing the cytoskeletal
network of developing myotubes has been reported (Bersten
et al. 1983). In addition, evidence has been presented for
alterations in TG2 expression and function in animals and
patients with heart failure (Sane et al. 2007). We examined
the cellular distribution of TG2 in myocytes from human heart
samples and revealed a particular site for TG2. The enzyme
displayed a regular localization along the Z-lines of myofibrils
(Fig. 5). Interestingly, in infarct heart failure, myofibrillar
disarray and Z band abnormalities are associated with a dis-
location of TG2 away from the Z-lines (data not shown).
TG2 location inside the cell under stressful conditions
Two different stress stimuli were used to evaluate the possible
modulation of TG2 distribution: starvation and oxidative
stress. Under nutrient-deprived conditions, cells responded
with a massive induction of autophagy. Under these condi-
tions, immunofluorescence microscopy analysis of p62 and
TG2 showed the colocalization of both the proteins inside
autophagic vacuoles (Fig. 1i). The immuno-gold analysis
demonstrated that, during autophagic induction, TG2 was
Fig. 1 Confocal microscopy
analysis of transglutaminase type
II (TG2) distribution in 2fTGH
cells. Cells cultured under normal
conditions (Ctr) or subjected to
starvation (Stv) were stained with
anti-TG2 (a, d, g, green); with
Tom20 (b, red), a marker of
mitochondria; with anti-
calreticulin (e, CRT, red), a
marker of endoplasmic reticulum;
or with anti-p62 (h, red)
localizing to autophagosomes.
TG2 was distributed in the
cytoplasmwith a granular pattern.
The merged image of the double-
fluorescence signals (Merge)
highlights the presence of TG2 on
mitochondria (c) and
endoplasmic reticulum (f) in
controls and on autophagic
vesicles (i) during autophagy
induction. Bar 6 μm
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associated with both protein aggregates (Fig. 6a) and
autophagosomes (Fig. 6b).
As is well known, mitochondria undergo dynamic struc-
tural alterations to meet changing needs and to maintain
homeostasis. Mitochondrial depolarization with carbonyl cy-
anide m-chlorophenylhydrazone (CCCP) causes severe mito-
chondrial alterations. Interestingly, TG2 is selectively recruit-
ed to damaged mitochondria as demonstrated by the presence
of gold granules on mitochondria of cells treated with CCCP
(Fig. 6c, d).
TG2 on the cell surface and extracellular release
Although initially being studied as an intracellular enzyme,
TG2 is now known to be secreted into the extracellular space
or onto the cell surface (Wang and Griffin 2012). We further
investigated the translocation of the enzyme to the cell surface
by analyzing pathological conditions known to trigger the
extra-cellular release of the enzyme, i.e., celiac disease.
Despite major advances in understanding the pathogenic
role of TG2 in celiac disease, several issues remain to be
elucidated, especially the question related to TG2 expression
by the enterocytes. The ultrastructural immunolocalization of
TG2 in the intestinal epithelium of celiac patients clearly
demonstrated an abundant presence of the enzyme at the level
of the enterocyte surface, especially on microvilli (Fig. 7b). In
samples from celiac patients after a gluten-free diet, the intes-
tinal mucosa displayed remission of the intestinal epithelial
damge (Fig. 7c). Quantification of TG2 revealed that the
expression of the enzyme on the surface of the enterocytes
of these patients was strongly reduced (Fig. 7d, e). The label-
ing density was 0.3 gold particles/μm2 in the biopsies of
Fig. 2 Immuno-gold detection of
TG2 in the nucleus of HEK293TG
cells shows positive labeling. a
During interphase, gold granules
are localized over the
euchromatin regions of the
nucleus (N), whereas
heterochromatin are devoid of
labeling. b No particles are
present at the level of the
nucleolus (Nu). c General view
showing the chromosomes
gathered at the metaphase plate.
d, e Higher magnification images
showing details of the condensed
chromatin clearly labeled with
clusters of gold granules. Bars
0.3 μm (a, b, d, e),3 μm (c)
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patients with celiac disease in remission, compared with
2.6 gold particles/μm2 in celiac biopsies.
A different aspect of TG2 and the extracellular environ-
ment relates to cancer cells. TG2 appears to be associated with
the early changes in cervical carcinogenesis (Del Nonno et al.
2011) and is involved in epithelial mesenchymal transition, a
key step in cancer metastasis (Lin et al. 2011). It has also been
reported to be over-expressed in highly aggressive and
chemo-resistant human brain, breast, lung and colorectal can-
cers and to be involved in the migration and invasion of cancer
cells such as breast cancer cells and neuroblastomas (Miyoshi
et al. 2010; Choi et al. 2011; Oh et al. 2011). Several studies
have reported a relationship between TG2 expression and
doxorubicin drug resistance but the mechanism has not been
fully clarified. Here, the distribution of TG2 was studied in
SK-n-BE(2) neuroblastoma cells after doxorubicin treatment
(10 μM for 3 h). The immunoelectron microscopic localiza-
tion showed that treatment with the anti-cancer drug doxoru-
bicin induced a translocation of the enzyme to the cell surface
at the level of plasma membrane projections (Fig. 8). Cell
Fig. 3 Ultrastructural detection
of TG2 in HEK293TG cells shows
distinct organelle localization of
the enzyme. a Electron
micrograph of a cytoplasmic
region containing two
mitochondria (m) exhibiting
negative or faint staining and a
lysosome (Ly) that is clearly
labeled. bMitochondrion
displaying gold granules
associated with both the outer
membrane and the matrix inside
the organelle. c Numerous gold
particles reveal that TG2 is
localized to the endoplasmic
reticulum (ER) compartment. d
Double-immunolabeling with
specific antibodies against TG2
(arrows) and calreticulin (small
gold granules) shows a positive
reaction on the ER cisternae. Bars
0.3 μm
Fig. 4 Representative electron
micrographs showing cell
membrane detection of TG2. a
Surface of the cells is usually
weakly labeled. b Gold particles
are preferentially found at the
level of cell membrane
projections (arrows). Bars0.3 μm
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surface microvilli displayed numerous microvesicles on their
inside; these appeared to be decorated with gold particles
indicating the presence of TG2. These observations also pro-
vide further insights regarding the possible mechanism uti-
lized by the cell to externalize TG2, suggesting that it is
delivered to the surface inside small vesicles (Fig. 8a).
Discussion
Given the broad function of TG2 in cell growth, survival,
death, differentiation, migration and extracellular matrix or-
ganization, the cell appears to adapt the dynamics of this
enzyme to meet specific sub-cellular needs or to respond to
stress or other stimuli. Substantial evidence indicates that the
sub-cellular location of TG2 is critical for the regulation of its
various biochemical activities, which subsequently trigger
diverse downstream events. However, the precise intracellular
distribution of TG2 to various sub-cellular compartments
remains largely undetermined.
Here, we used an immuno-gold ultrastructural method to
establish the fine sub-cellular localization of TG2 under var-
ious conditions, either physiological or non-physiological.
The data obtained show that TG2 is not freely dispersed in
the cell but is always associated with a cell structure and that
the presence of TG2 in a cell compartment is not fixed but is
determined by the physiological conditions, stress stimuli, or
activity state of the cell (Fig. 9).
The presence of TG2 in the nucleus has been reported in
various cell types. It generally represents 5–7 % of the total
cellular TG2, although this amount can vary depending on cell
type, treatment and experimental conditions (Lesort et al.
1998). Nuclear accumulation of TG2 is induced by a number
of stressors; in particular, elevated intracellular calcium
levels increase the translocation of TG2 to the nucleus
Fig. 5 Electron micrographs of myofibrils from human normal myocar-
dium. Immuno-gold localization showing the presence of TG2 (arrows)
at the level of the Z-band (Z). Bar0.3 μm
Fig. 6 TG2 distribution in
HEK293TG cells under stressful
conditions. a, b Under nutrient-
deprived conditions, TG2 is
found in protein aggregates (a)
and within autophagosomes (b).
c, d Treatment with an uncoupler
of oxidative phosphorylation in
mitochondrial systems induces
clearly visible injury of
mitochondria (m); under these
conditions, immuno-gold
detection shows the presence of
TG2 inside damaged
mitochondria (N nucleus). Bars
0.3 μm
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(Gundemir et al. 2012). Once in the nucleus, TG2 might
mediate transcriptional regulation by modulating the ex-
pression of a variety of transcription factors such as
nuclear factor kappa Bα and Sp1 and thereby indirectly
affect the transcription of a multitude of genes (Mann
et al. 2006; Tatsukawa et al. 2009).
Fig. 7 Electron micrographs of
duodenal mucosa from celiac
patients (a, b) and from celiac
patients on a gluten-free diet (c,
d). a Representative example of
mucosal injury in a celiac patient:
enterocytes display rarefaction
and partial disappearance of
microvilli. b Higher
magnification of apical surface
showing numerous gold granules:
the presence of TG2 appears
mostly to be associated with the
microvilli on the luminal surface
of enterocytes. c Ultrastructural
features of enteric mucosa in a
patient with celiac disease in
remission after a gluten-free diet:
a marked recovery of tissue
architecture is visible, with
virtually absent alterations in the
brush border. d Higher
magnification of the top surface
facing the lumen: a change in the
distribution of TG2 is
demonstrated by the presence of
just a few granules (arrows)
localized underneath the
microvilli. Bars3 μm (a,c),
1.5 μm (b,d). e Quantification of
TG2 immuno-gold labeling
within the apical membranes of
enterocytes in celiac patients and
in celiac patients on a gluten free-
diet. The bar chart shows the
decrease in the number of gold
particles per square micrometer
within the apical surface of
enterocytes of a patient in
remission (gray) versus a
diseased patient (black). Error
bars are±SEM. ***P<0.0001
Fig. 8 Immuno-gold localization
of TG2 in SK-n-BE(2)
neuroblastoma cells treated with
doxorubicin. The anti-cancer drug
doxorubicin causes an extensive
distribution of TG2 at the plasma
membrane. Gold particles seem to
be associated with both dense
vesicles (arrowheads) located
under the cell surface (a) and with
protruding cell processes (b).
Bars0.15 μm
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Previous data, obtained by immuno-blot on cell fractions,
have demonstrated that about 90 % of nuclear TG2 is associ-
ated with chromatin and the remaining with nuclear matrix
(Lesort et al. 1998). Here, we have revealed that, in cells under
non-proliferating conditions, TG2 is not widely distributed
within the chromatin but is confined to the euchromatin, the
de-condensed chromatin domains required to allow transcrip-
tion. Given this finding, we do not expect to find TG2 on the
chromosome of proliferating cells. Nevertheless, an exact
opposite arrangement is observed during mitosis, when TG2
has been detected on highly condensed chromatin. The major
change in nuclear structure during mitosis is chromosome
condensation. The interphase chromatin, which is packaged
into nucleosomes, condenses approximately a further
thousand-fold to form the compact chromosomes seen in
mitotic cells. Phosphorylation of histone H3 has been found
to be required for the condensation of mitotic chromosomes
and histone H1 is phosphorylated during mitosis in most cells,
even though its phosphorylation seems to be unnecessary (Xu
et al. 2009). All four mammalian core histones (H2A, H2B,
H3 and H4) have been shown to be glutaminyl substrates of
TG2 and their crosslinking contributes to chromatin conden-
sation during the onset of apoptosis (Kim et al. 2002). In
addition, histones are also substrates for TG2 kinase activity
(Mishra et al. 2006). Biochemical and in vitro experiments
have shown that TG2 can phosphorylate H3 and, to a lesser
extent, H1. The TG2-induced phosphorylation of H3 occurs at
Ser10, a site shown to be crucial for chromosome condensa-
tion and cell cycle progression (Nowak and Corces 2004). In
recent years, chromatin research has revealed that histones are
targets of multiple post-translational modifications, including
phosphorylation, acetylation, methylation, ubiquitination and
ADP ribosylation. These modifications, which occur on dis-
tinct amino acid residues on specific histones and within
chromatin at certain genomic regions, make it possible to
regulate two opposite processes, such as transcriptional acti-
vation and repression, by using the same amino acid sequence
within a histone (Cohen et al. 2011). Considering biochemical
evidence and the observed presence of TG2 on both euchro-
matin domains and condensed chromatin, we suggest that
Fig. 9 The multifunctional enzyme TG2 is found in various sub-cellular
compartments in which its activity is regulated by interaction with diverse
factors depending on its location. The identification of changes of
location under particular cell conditions might help in the comprehension
of unknown functions of TG2
Cell Tissue Res (2014) 358:793–805 801
TG2 represents one of the effector elements in this network of
modifications that control gene expression, chromosome con-
densation and disease processes.
TG2 appears to exert a double-function by also influencing
cell fate at the level of another cell compartment: the
mitochondrium. A strong association between oxidative stress
and TG2 up-regulation has been reported; this might result in
cell survival or apoptosis (Caccamo et al. 2012). We have
previously shown that TG2 affects mitochondrial function and
regulates the energy balance of the cell (Piacentini et al. 2002).
Upon cell death induced by staurosporine treatment, TG2
cross-links Bax on the outer mitochondrial membrane
resulting in the stabilization of the Bax oligomer and, conse-
quently, in the opening of pores in the outer mitochondrial
membrane and in membrane permeabilization (Rodolfo et al.
2004). In addition TG2 is involved in the regulation of the
respiratory chain. Through its PDI activity, the enzyme can
stabilize the assembly and activity of some members of the
mitochondrial respiratory chain (Malorni et al. 2009). In spite
of these data, some authors appear to be sceptical about the
localization of TG2 insidemitochondria and are more prone to
consider the enzyme as being loosely associated with the
outside of the mitochondria (Gundemir et al. 2012).
Utilizing the immuno-gold technique, we here clearly show
that TG2 can be localized in association with the outer mem-
brane of mitochondria but also inside mitochondria. Of par-
ticular interest is the finding that the enzyme is especially
recruited to mitochondria that have lost their functional integ-
rity, such as after cell treatment with CCCP, an uncoupling
agent that dissipates the mitochondrial membrane potential.
These data support the hypothesis that TG2 exerts, at the
mitochondrial level, an important role both in physiology
and pathology, contributing to set the threshold of cell redox
state homeostasis and thus playing a pro-survival or cell-
death-inducing function, with special relevance for all those
pathologies (neurodegenerative, miocardial dysfunction) in
which mitochondrial functionality is of primary importance
(Piacentini et al. 2011).
Importantly, our data revealed that TG2 is present on the
ER. Several BCL-2 family members have also been found at
this location, where they have been reported to be involved in
the regulation of calcium homeostasis, autophagy and ER
stress responses (Szegezdi et al. 2009). Our results might shed
light on other possible functions of TG2 as yet unknown. In
this regard, recent work based on a cellular model of
Parkinson's disease provided evidence of ER-associated
TG2, which the authors propose could have a direct impact
on ER function in the pathogenesis of this disease (Verhaar
et al. 2012).
In addition to the intracellular functions exerted by TG2,
the enzyme is involved in extracellular processes: TG2 medi-
ates cell adhesion in cooperation with fibronectin and the
integrins (Verderio et al. 2003; Zemskov et al. 2006) and
supports the polymerization of fibronectin and collagen
(Jones et al. 1997). As an extracellular protein, TG2 has an
established role in celiac disease, both in increasing the im-
munogenicity of gluten antigens and also as an autoantigen
(Klöck et al. 2012). Despite major advances in understanding
the pathogenic role of TG2 in celiac disease, several issues
remain to be elucidated. These include the mechanism of TG2
externalization and the role of enterocytes as primary sites of
gliadin modification by TG2. Immunohistochemical studies
have shown that TG2 is expressed in normal small intestine
and that such expression is slightly increased in untreated
celiac small intestinal mucosa in which TG2 is detected at
the level of muscularis mucosae and pericryptal fibroblasts
adjacent to enterocytes (Di Sabatino et al. 2012). TG2 expres-
sion has also been detected in celiac enterocytes (Biagi et al.
2006). Here, we showed that celiac enterocytes of untreated
patients specifically express TG2 on their apical surface and
along microvilli facing the intestinal lumen, as opposed to
normal control enterocytes that display the presence of posi-
tive reaction exclusively at the level of the basolateral mem-
brane. Our observations reveal no evidence for the presence of
the enzyme inside the enterocytes, thus supporting the idea
that gliadin peptides come into contact with TG2 only outside
enterocytes.
Several studies have suggested that extracellular TG2 is
also involved in migration of tumor cells by binding to fibro-
nectin or by keratin reorganization (Park et al. 2011; Chen
et al. 2010). TG2 can influence several aspects of cancer cells
by the activation of survival pathways or the inhibition of
apoptosis. In addition, TG2 has been reported to mediate
chemo-resistance. The exact mechanism through which TG2
expression mediates drug resistance is not completely under-
stood; however, doxorubicin resistance seems to be dependent
upon the action of TG2 on ECM proteins, thereby promoting
the interaction between integrins and fibronectin (Herman
et al. 2006). In this study, we showed that TG2 is rapidly
externalized by neuroblastoma cells after doxorubicin treat-
ment. These results also add information about the process of
TG2 externalization. The available data in the literature
concerning mechanisms of TG2 translocation to the plasma
membrane suggest at least two possible routes: the formation
of microparticles ranging between 500 and 1000 nm in size
(Van den Akker et al. 2012) or the involvement of an
endosomal recycling pathway (Zemskov et al. 2011). Our
immuno-gold analysis revealed that doxorubicin induces the
externalization of TG2 by utilizing small vesicles (around 50–
100 nm) apparently formed under the plasma membrane and
perhaps originating from the ER, as suggested by double-
staining with calreticulin (data not shown). These data agree
with published studies showing the involvement of TG2 in the
regulation of exocytosis or neurotransmitter release
(Pastuszko et al. 1986; Gobbi et al. 1996; Santhanam et al.
2011) and will require further investigation.
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A number of studies have demonstrated that TG2, in addi-
tion to its role on ECM scaffolds, can affect cell plasticity. In
agreement with this, TG2 has recently been established to be
able to mediate axonal microtubules stability by the
polyamination of tubulins (Song et al. 2013). By contrast,
TG2 can regulate the cell contractile response by modulating
F-actin polymerization and myosin light chain phosphoryla-
tion (Spurlin et al. 2009). TG2 is widely expressed by cardiac
and vascular cells including endothelial and smooth muscle
cells, which constitutively express TG2 at high levels.
Cardiomyocytes from adult hearts also express TG2.
Evidence exists for alterations in TG2 expression and function
in animals and patients with heart failure. TG2 is up-regulated
during cardiac hypertrophy and heart failure in animal models,
whereas its activity (GTP binding and GTPase) has been
found to be down-regulated in patients with ischemic and
dilated cardiomyopathies (Sane et al. 2007). Here, we provide,
for the first time, evidence for the specific location of TG2 in
cardiac myocytes Z-disc. The Z-disc is a critical element in the
regulation of myocardial function by changes in the cell
stresses and strains that accompany altered hemodynamic
demands. Evidence of an association between cardiac Z-
discs and signaling proteins such as kinases, phosphatases
and Ca2+-binding proteins indicates an important but poorly
understood potential for Z-disc involvement in the develop-
ment of myocardial hypertrophy, myopathies and heart failure
(Pyle and Solaro 2004). Our findings suggest that TG2 is part
of the network of proteins making up the Z-disc; it might be
active in the stabilization of structural proteins or function as a
signaling protein. According to this point of view, the bio-
chemical and in vitro data in the literature indicate a strong
noncovalent interaction between the transglutaminase mole-
cule and the myofibril Z line (Gard and Lazarides 1979).
Although the details of the interaction between TG2 and
cardiac Z-discs are unknown, our finding of the dislodgment
of TG2 in myofibrils during heart failure appears intriguing.
The accurate function of proteins and their interaction
networks is heavily dependent on the proper localization
of each protein. Knowing the location of a protein
within its cellular environment is critical for an under-
standing of the regulatory mechanisms by which it is
controlled. With the utilization of immunoelectron mi-
croscopy as an experimental tool, this study provides
direct information concerning TG2 cellular and sub-
cellular localization. Even if other methodological ap-
proaches have been adopted to date to define TG2
locations, electron microscopy remains the most accu-
rate technique for demonstrating the relationship be-
tween protein distribution and morphological events. In
this study, we also described a possible unrecognized
location of TG2. Our findings thus provide useful in-
sights about the functions and regulation of this pleio-
tropic enzyme.
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